Financial Data and Key Metrics Changes - The company generated consolidated revenue of $329 million, representing a 13% growth year-over-year, primarily driven by strong growth in healthcare services [4][17] - Senior revenues declined to $59 million from $93 million a year ago, a decrease of 37%, attributed to lower policy production due to new eligibility requirements [4][18] - The company reported a quarterly EBITDA loss of $32 million, which was below the guided loss range of $25-$30 million [8][17] Business Line Data and Key Metrics Changes - The senior business segment experienced a 32% reduction in policy production compared to the previous year, leading to a negative EBITDA of $21 million [5][18] - Healthcare services EBITDA was impacted by changes in drug reimbursement rates, with an expected second-quarter adjusted EBITDA of approximately break-even [6][20] - The life insurance business saw nearly 20% revenue growth, driven by balanced growth in term life and final expense policies [22] Market Data and Key Metrics Changes - The company noted an elevated level of policyholder volatility due to shifts in planned benefits and structures from carriers, which is expected to continue in the upcoming AEP season [9][10] - The Medicare Advantage (MA) market is experiencing a high level of consumer engagement as beneficiaries evaluate options, with a focus on simplifying benefits [34][36] Company Strategy and Development Direction - The company aims to leverage its data-enabled agent-led model as a competitive advantage in the dynamic Medicare Advantage market [9][10] - There is a strategic focus on improving policyholder retention and understanding their plans better, which is seen as critical in the current environment [10][27] - The company is negotiating a longer-term reimbursement agreement with its PBM partner to enhance visibility and predictability for its healthcare services business [6][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term economics of healthcare services despite short-term reimbursement challenges [7][20] - The company remains optimistic about the upcoming AEP and OEP seasons, supported by strong agent retention and successful preseason hiring [10][23] - The fiscal 2026 financial outlook remains unchanged at $1.65 billion to $1.75 billion in revenue and $120 million to $150 million in adjusted EBITDA [23] Other Important Information - The company is actively working on improving medication adherence through its SelectRx program, which has shown positive results in reducing hospital days and improving health outcomes [16][12] - The company is expanding its healthcare services offerings to address social determinants of health, enhancing its value proposition to members [31] Q&A Session Summary Question: Concerns about SelectRx reimbursement headwinds - Management reassured that they are in constructive discussions with their PBM partner to solidify a longer-term agreement, emphasizing the clinical value of their solution [24][25] Question: Impact of SelectRx on LTV - Management noted that while they observe improved persistency among SelectRx members, this is not currently factored into the lifetime value calculations [25][26] Question: Strategies for helping policyholders understand their plans - Management highlighted their proactive approach to assist beneficiaries in navigating plan changes, utilizing AI and data to enhance customer engagement [27][29] Question: Market dynamics in the AEP season - Management indicated that the current AEP season is dynamic, with high consumer engagement and a focus on profitability among carriers [34][36] Question: Managing growth in SelectRx - Management emphasized a measured approach to member growth, focusing on profitability and partnerships with payers that value their services [38][40]